Advertisement
Expression of concern
Open Access |
10.1172/JCI214632
Find articles by Lu, M. in: PubMed | Google Scholar
Find articles by Li, K. in: PubMed | Google Scholar
Find articles by Wu, S. in: PubMed | Google Scholar
Find articles by Zheng, Z. in: PubMed | Google Scholar
Find articles by Li, X. in: PubMed | Google Scholar
Find articles by Wang, S. in: PubMed | Google Scholar
Find articles by Yu, H. in: PubMed | Google Scholar
Find articles by Liu, C. in: PubMed | Google Scholar
Find articles by Jiang, Y. in: PubMed | Google Scholar
Find articles by Song, X. in: PubMed | Google Scholar
Find articles by
Liu, Y.
in:
PubMed
|
Google Scholar
|
Find articles by
Guo, X.
in:
PubMed
|
Google Scholar
|
Published November 16, 2026 - More info
Huntington’s disease (HD) is a fatal neurodegenerative disorder characterized by progressive motor dysfunction, cognitive decline, and striatal neuron degeneration, primarily affecting medium spiny neurons (MSNs). Despite extensive research, the underlying metabolic vulnerabilities contributing to HD pathogenesis remain poorly understood. In this study, we employed RNA-seq and metabolomics analyses to identify marked dysregulation of 1-carbon metabolism in HD. We validated that SHMT2, a key mitochondrial enzyme in the mitochondrial 1-carbon pathway, was substantially downregulated in HD patient–derived iPSC-differentiated human striatal organoids (hSOs) and YAC128 mice. Functionally, pharmacologic inhibition or genetic deletion of SHMT2 exacerbated mutant huntingtin aggregation, induced MSN degeneration in hSOs, and impaired motor function in WT mice. Conversely, SHMT2 overexpression attenuated MSN degeneration in HD-hSOs and improved motor performance in YAC128 mice. Mechanistically, SHMT2 deficiency led to accumulation of homocysteine, which interacted with AARS1 and suppressed histone lactylation, thereby perturbing transcriptional regulation and associating with neurodegenerative phenotypes. Finally, we demonstrated that the HD clinical drug haloperidol modulated SHMT2 expression and restored histone lactylation, providing a pharmacologic tool to probe SHMT2-dependent metabolic and epigenetic regulation in HD models. These findings highlight a metabolic-epigenetic axis as a promising therapeutic target for HD.
Mingqin Lu, Kexin Li, Shanshan Wu, Zhilong Zheng, Xinyue Li, Shengda Wang, Hanwen Yu, Chunyue Liu, Yueqing Jiang, Xueqin Song, Yan Liu, Xing Guo
Original citation: J Clin Invest. 2026;136(9):e196094. https://doi.org/10.1172/JCI196094
Citation for this expression of concern: J Clin Invest. 2026;136(22):e214632. https://doi.org/10.1172/JCI214632
The authors recently alerted the Editors to errors in the source data and figures for Figure 2G and Supplemental Figures 3A, 5A, and 5G that were identified in response to an institutional mandate for a post-publication audit of the data. Although the authors have indicated that independent lines of investigation support the article’s conclusions, the Editors are issuing this Expression of Concern to alert readers to the issues. We have requested institutional oversight into this matter and will alert readers to the outcome when the institutional evaluation is complete.